ArticleCell2023
A membrane-associated MHC-I inhibitory axis for cancer immune evasion.
Open access · greenAbstract read
In one paragraph
Article in Cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 133 papers.
0numbers the graph read from it
0cells of the map it votes in
133citing papers in PubMed
27.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
133 citing papers in PubMed, 168 citations in OpenAlex.
- FGF18 mediates fibroblast-leukemia cross talk to promote acute myeloid leukemia progression.Blood · 2026Article
- LARS2 reprograms mitochondrial metabolism and epigenetically upregulates MHC-I to boost antitumor immunity in nasopharyngeal carcinoma.Journal for immunotherapy of cancer · 2026Article
- Maternal sleep deprivation reshapes offspring hippocampal development through a Trem2-centered microglial program revealed by single-nucleus and spatial transcriptomics.Molecular psychiatry · 2026Article
- Bibliometric and visual analysis: A comprehensive tracking of global research trends on ablation and tumor immune microenvironment from 2016 to 2025.Translational oncology · 2026Article
- The aryl hydrocarbon receptor inhibits antigen presentation to promote progression of pancreatic ductal adenocarcinoma.Journal of advanced research · 2026Article
- Targeting TOMM40 unleashes immunogenic mitophagy to facilitate antigen presentation and immunotherapy sensitization.Journal for immunotherapy of cancer · 2026Article
- EpiSNPdb: A Comprehensive Database of Genetic Epistasis Across Multiple Cancer Types.Current issues in molecular biology · 2026Article
- Krüppel-like factor 4 downregulation during esophageal cancer formation facilitates immune evasion and impairs immunotherapy.Signal transduction and targeted therapy · 2026Article
- Targeting E3 ubiquitin ligases: Mechanistic breakthroughs and novel clinical translation pathways for tumor radioimmunotherapy.Molecular cancer · 2026Review
- Programmable mRNA 3'UTR engineering restores MHC-I and overcomes immune evasion in prostate cancer.Nature biomedical engineering · 2026Article
- Lipogenesis-driven EGFR palmitoylation enables metastatic immune evasion in triple-negative breast cancer.bioRxiv : the preprint server for biology · 2026Article
- PSD3 links autophagic flux to MHC-I-associated immune modulation in esophageal squamous cell carcinoma.Apoptosis : an international journal on programmed cell death · 2026Article
- Reinvigorating COTL1Nature cell biology · 2026Article
- Uncoupling tumor immunogenicity from cell death with platinum(IV)-antibody conjugates.National science review · 2026Article
- Dual-stress-responsive-pathways prevent HCC initiation via p53 suppression of MTHFD1L-RNA mResearch square · 2026Article
- Breast cancer immunotherapy: mechanisms of immune evasion, biomarkers, and emerging therapeutic strategies.Molecular cancer · 2026Review
- Novel Insights into the Role of circRNAs in Cancer Immunotherapy Resistance and Clinical Implications.International journal of molecular sciences · 2026Review
- Cold atmospheric plasma-engineered nanovaccine with spatiotemporal sequential immunization reprograms antitumor immunity.Science advances · 2026Article
- Ceramide disrupts TM9SF2-PGK1 axis to redirect PD-L1 trafficking and enhance antitumor immunity.Nature communications · 2026Article
- ULK1 drives NDP52-mediated selective autophagic degradation of MHC-I to promote immune evasion in HPV-positive head and neck cancer.bioRxiv : the preprint server for biology · 2026Article
73 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
25 authors at 5 institutions in 1 country.
Xufeng ChenDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA; The Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA.
Qiao LuDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA; The Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA.
Hua ZhouApplied Bioinformatics Laboratories, New York University Grossman School of Medicine, New York, NY 10016, USA.
Jia LiuDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA; The Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA.
Bettina NadorpDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA; The Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA.
Audrey LasryDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA; The Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA.
Zhengxi SunDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA; The Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA.
Baoling LaiDepartment of Neuroscience and Physiology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Gergely RonaThe Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA; Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY 10016, USA; Howard Hughes Medical Institute, New York University Grossman School of Medicine, New York, NY 10016, USA.
Jiangyan ZhangDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA; The Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA.
Michael CammerMicroscopy Core, Division of Advanced Research Technologies, New York University Grossman School of Medicine, New York, NY 10016, USA.
Kun WangDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA; The Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA.
Wafa Al-SantliDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA; The Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA.
Zoe CiantraDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Qianjin GuoDepartment of Medicine, Division of Hematology and Medical Oncology, Mays Cancer Center, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Jia YouDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA; The Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA.
Debrup SenguptaDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT 06519, USA.
Ahmad BoukhrisDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA; The Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA.
Hongbing ZhangEureka Therapeutics Inc., Emeryville, CA 94608, USA.
Cheng LiuEureka Therapeutics Inc., Emeryville, CA 94608, USA.
Peter CresswellDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT 06519, USA.
Patricia L M DahiaDepartment of Medicine, Division of Hematology and Medical Oncology, Mays Cancer Center, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Michele PaganoThe Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA; Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY 10016, USA; Howard Hughes Medical Institute, New York University Grossman School of Medicine, New York, NY 10016, USA.
Iannis AifantisDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA; The Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA. Electronic address: ioannis.aifantis@nyulangone.org.
Jun WangDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA; The Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA. Electronic address: jun.wang@nyulangone.org.
New York University · USNYU Langone Health · USEureka Therapeutics (United States) · USThe University of Texas Health Science Center at San Antonio · USYale University · US
Funding
Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MARK Reid PHILIPS · 1985 to 2026
$83.1MINSTITUTE FOR INTEGRATION OF MEDICINE & SCIENCE: A PARTNERSHIP TO IMPROVE HEALTHUL1RR025767 · NCRR · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CLARK, ROBERT A · 2008 to 2011
$23.8MInstitute for Integration of Medicine & Science: A Partnership to Improve HealthUM1TR004538 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI ROBERT A CLARK, Kenneth M Hargreaves · 2023 to 2026
$22.3MRole of TET2 mutations in malignant transformation and acute myeloid leukemiaR01CA173636 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI AIFANTIS, IANNIS, LEVINE, ROSS L · 2013 to 2022
$6.3MEvaluating the impact of genetic ancestry on the biology and drug response profile of pheochromocytoma and paraganglioma-derived organoid modelsR01CA264248 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DAHIA, PATRICIA LEAL, SORAGNI, ALICE · 2021 to 2025
$3.2MElucidating the Role of Cancer-Associated FGL1 in Tumor Immunity and Developing FGL1-Guided Anti-LAG-3 Cancer ImmunotherapyR37CA273333 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI JUN WANG · 2022 to 2026
$2.8MTargeting an RNA Binding Protein Network in Acute Myeloid LeukemiaR01CA242020 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ABDEL-WAHAB, OMAR, AIFANTIS, IANNIS · 2020 to 2024
$2.7MRegulation of the cell proliferation by CRL ubiquitin ligases-diversity supplementR35GM136250 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MICHELE PAGANO · 2020 to 2026
$2.7MmRNA stability and its impact on hematopoiesis and acute leukemiaR01CA266212 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Iannis Aifantis · 2022 to 2026
$2.7MRegulation of emergency hematopoiesis by the ubiquitin-proteasome systemR01HL159175 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI AIFANTIS, IANNIS, BUSINO, LUCA · 2021 to 2024
$2.5MThe cohesin complex as a tumor suppressor in myeloid leukemiaR01CA216421 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS, LEVINE, ROSS L · 2017 to 2021
$2.5MMechanisms of enhancer regulation in leukemiaR01CA228135 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS · 2019 to 2023
$2.5MHoward Hughes Medical InstituteNCATS NIH HHS UM1 TR004538NCI NIH HHS P30 CA016087NCI NIH HHS R01 CA173636NCI NIH HHS R01 CA216421NCI NIH HHS R01 CA228135NCI NIH HHS R01 CA242020NCI NIH HHS R01 CA264248NCI NIH HHS R01 CA266212NCI NIH HHS R01 CA269898NCI NIH HHS R01 CA283574NCI NIH HHS R37 CA273333NCRR NIH HHS UL1 RR025767NHLBI NIH HHS R01 HL159175NIAID NIH HHS R21 AI163924NIGMS NIH HHS R01 GM114102NIGMS NIH HHS R35 GM136250
Abstract
Immune-checkpoint blockade has revolutionized cancer treatment, but some cancers, such as acute myeloid leukemia (AML), do not respond or develop resistance. A potential mode of resistance is immune evasion of T cell immunity involving aberrant major histocompatibility complex class I (MHC-I) antigen presentation (AP). To map such mechanisms of resistance, we identified key MHC-I regulators using specific peptide-MHC-I-guided CRISPR-Cas9 screens in AML. The top-ranked negative regulators were surface protein sushi domain containing 6 (SUSD6), transmembrane protein 127 (TMEM127), and the E3 ubiquitin ligase WWP2. SUSD6 is abundantly expressed in AML and multiple solid cancers, and its ablation enhanced MHC-I AP and reduced tumor growth in a CD8
Indexed as
Histocompatibility Antigens Class INeoplasmsTumor EscapeAntigen PresentationCD8-Positive T-LymphocytesHLA AntigensHumansUbiquitin-Protein LigasesHistocompatibility Antigens Class IHLA AntigensUbiquitin-Protein LigasesWWP2 protein, humanantigen presentationcancerimmune evasionlysosomal degradationMHC-ISUSD6T cellTMEM127ubiquitinationWWP2
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.